Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CRMD, ITRM and PHG By: The Klein Law Firm via AccessWire September 19, 2021 at 10:21 AM EDT NEW YORK, NY / ACCESSWIRE / September 19, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.CorMedix Inc. (NASDAQ:CRMD)Class Period: October 16, 2019 - May 13, 2021Lead Plaintiff Deadline: September 20, 2021During the class period, CorMedix Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) deficiencies existed with respect to an investigational drug product, DefenCath's, manufacturing process and/or at the facility responsible for manufacturing DefenCath; (ii) in light of the foregoing deficiencies, the Food and Drug Administration was unlikely to approve the DefenCath new drug application for catheter-related bloodstream infections in its present form; (iii) Defendants had downplayed the true scope of the deficiencies with DefenCath's manufacturing process and/or at the facility responsible for manufacturing DefenCath; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.Learn about your recoverable losses in CRMD: https://www.kleinstocklaw.com/pslra-1/cormedix-inc-loss-submission-form?id=19690&from=1Iterum Therapeutics Plc (NASDAQ:ITRM)Class Period: November 30, 2020 - July 23, 2021Lead Plaintiff Deadline: October 4, 2021Iterum Therapeutics Plc allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) the sulopenem New Drug Application ("NDA") lacked sufficient data to support approval for the treatment of adult women with urinary tract infections caused by designated susceptible microorganisms proven or strongly suspected to be nonsusceptible to a quinolone; (ii) accordingly, it was unlikely that the Food and Drug Administration would approve the sulopenem NDA in its current form; (iii) Defendants downplayed the severity of issues and deficiencies associated with the sulopenem NDA; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.Learn about your recoverable losses in ITRM: https://www.kleinstocklaw.com/pslra-1/iterum-therapeutics-plc-loss-submission-form?id=19690&from=1Koninklijke Philips N.V. (NYSE:PHG)Class Period: February 25, 2020 - June 11, 2021Lead Plaintiff Deadline: October 15, 2021During the class period, Koninklijke Philips N.V. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Philips had deficient product manufacturing controls or procedures; (ii) as a result, the Company's Bi-Level PAP and CPAP devices and mechanical ventilators were manufactured using hazardous materials; (iii) accordingly, the Company's sales revenues from the foregoing products were unsustainable; (iv) the foregoing also subjected the Company to a substantial risk of a product recall, in addition to potential legal and/or regulatory action; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.Learn about your recoverable losses in PHG: https://www.kleinstocklaw.com/pslra-1/koninklijke-philips-n-v-loss-submission-form?id=19690&from=1Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.CONTACT:J. Klein, Esq.Empire State Building350 Fifth Avenue59th FloorNew York, NY 10118jk@kleinstocklaw.comTelephone: (212) 616-4899Fax: (347) 558-9665www.kleinstocklaw.comSOURCE: The Klein Law FirmView source version on accesswire.com: https://www.accesswire.com/664668/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-CRMD-ITRM-and-PHG Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CRMD, ITRM and PHG By: The Klein Law Firm via AccessWire September 19, 2021 at 10:21 AM EDT NEW YORK, NY / ACCESSWIRE / September 19, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.CorMedix Inc. (NASDAQ:CRMD)Class Period: October 16, 2019 - May 13, 2021Lead Plaintiff Deadline: September 20, 2021During the class period, CorMedix Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) deficiencies existed with respect to an investigational drug product, DefenCath's, manufacturing process and/or at the facility responsible for manufacturing DefenCath; (ii) in light of the foregoing deficiencies, the Food and Drug Administration was unlikely to approve the DefenCath new drug application for catheter-related bloodstream infections in its present form; (iii) Defendants had downplayed the true scope of the deficiencies with DefenCath's manufacturing process and/or at the facility responsible for manufacturing DefenCath; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.Learn about your recoverable losses in CRMD: https://www.kleinstocklaw.com/pslra-1/cormedix-inc-loss-submission-form?id=19690&from=1Iterum Therapeutics Plc (NASDAQ:ITRM)Class Period: November 30, 2020 - July 23, 2021Lead Plaintiff Deadline: October 4, 2021Iterum Therapeutics Plc allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) the sulopenem New Drug Application ("NDA") lacked sufficient data to support approval for the treatment of adult women with urinary tract infections caused by designated susceptible microorganisms proven or strongly suspected to be nonsusceptible to a quinolone; (ii) accordingly, it was unlikely that the Food and Drug Administration would approve the sulopenem NDA in its current form; (iii) Defendants downplayed the severity of issues and deficiencies associated with the sulopenem NDA; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.Learn about your recoverable losses in ITRM: https://www.kleinstocklaw.com/pslra-1/iterum-therapeutics-plc-loss-submission-form?id=19690&from=1Koninklijke Philips N.V. (NYSE:PHG)Class Period: February 25, 2020 - June 11, 2021Lead Plaintiff Deadline: October 15, 2021During the class period, Koninklijke Philips N.V. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Philips had deficient product manufacturing controls or procedures; (ii) as a result, the Company's Bi-Level PAP and CPAP devices and mechanical ventilators were manufactured using hazardous materials; (iii) accordingly, the Company's sales revenues from the foregoing products were unsustainable; (iv) the foregoing also subjected the Company to a substantial risk of a product recall, in addition to potential legal and/or regulatory action; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.Learn about your recoverable losses in PHG: https://www.kleinstocklaw.com/pslra-1/koninklijke-philips-n-v-loss-submission-form?id=19690&from=1Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.CONTACT:J. Klein, Esq.Empire State Building350 Fifth Avenue59th FloorNew York, NY 10118jk@kleinstocklaw.comTelephone: (212) 616-4899Fax: (347) 558-9665www.kleinstocklaw.comSOURCE: The Klein Law FirmView source version on accesswire.com: https://www.accesswire.com/664668/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-CRMD-ITRM-and-PHG